Navigation Links
Medinox Announces Clinical Results of Naproxen Prodrug
Date:5/26/2009

SAN DIEGO, May 26 /PRNewswire/ -- Medinox, Inc. (Carlsbad, CA) and its development partner, Logical Therapeutics, Inc. (Waltham, MA) announced the results of a double-blind, randomized, active comparator study of LT-NS001 (formerly MX-1094) vs naproxen, in subjects 45 to 70 years of age. LT-NS001 is a novel, patented NCE prodrug of the popular non-steroidal anti-inflammatory drug (NSAID) naproxen, which is being developed to significantly reduce the GI safety risks, including the formation of ulcers, associated with naproxen. Naproxen is widely regarded as the NSAID with the most favorable cardiovascular safety profile among all of the drugs in this class.

In this study, subjects underwent upper endoscopies at baseline and on day seven. Subjects receiving LT-NS001 experienced statistically significantly fewer endoscopically confirmed gastric ulcers compared to subjects receiving naproxen.

LT-NS001 is pharmacologically inactive as an NSAID in the GI tract, but once absorbed into the blood stream, it is converted rapidly and quantitatively to naproxen. It is being developed to provide therapeutic levels of naproxen while avoiding high local concentrations of naproxen in the GI tract, thereby reducing the local GI toxicity associated with conventional naproxen.

LT-NS001 has been studied in various randomized controlled single-dose and multiple-dose clinical studies. In all cases, there were no serious adverse events and LT-NS001 was well tolerated. Moreover, when the subjects were dosed twice daily with LT-NS001, plasma concentrations of naproxen were within the therapeutic range.

NSAIDs are the most common medications taken worldwide for the treatment of pain, inflammation, fever and arthritics, including both rheumatoid arthritis (RA) and osteoarthritis (OA). The use of NSAIDs is associated with serious side effects, the most frequent being an increased rate of gastric and duodenal ulcers. In the United States alone, the direct costs of treating ulcer complications associated with NSAID use exceed $4 billion a year. Serious NSAID-induced GI complications such as hemorrhage and perforation are directly responsible for about 20,000 deaths per year in the United States.

About Medinox, Inc.

Medinox, based in Carlsbad, CA, is a privately held biotechnology company, focused on developing novel therapeutic drugs for treating inflammation and septic shock. For more information about Medinox and its products, visit the company's website at www.medinox.com., or contact Monte Lai, Ph.D., President & CEO of Medinox, Inc. at cslai@medinox.com.

About Logical Therapeutics, Inc.

Based in Waltham, MA, Logical Therapeutics Inc. is a venture-backed, privately held biotechnology company focused on the development of products that treat diseases associated with inflammation. Logical's investors include SV Life Sciences, Burrill and Company, Novo Ventures A/S and Novitas Capital. For more information on Logical Therapeutics, visit the company's website at www.logicaltherapeutics.com.


'/>"/>
SOURCE Medinox, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Healthy Rebates, Inc. Announces the Launch of My HSA Rewards
2. Pro-cell Announces a Knock at the Door of Emerging Markets
3. March of Dimes Announces Nursing Scholarship Recipients
4. The Gout & Uric Acid Education Society (GUAES) Announces New Survey Results Highlighting Major Gaps in Public Awareness of Gout
5. AIM Health Group Inc. reports largest quarterly profit since going public and announces filing of financial results for the three months ended March 31, 2009 on SEDAR
6. Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes
7. QLT Announces Court Response to Motion to Dismiss and Removal of Case to Federal Court
8. Authentidate Holding Corp. Announces Results From Annual Meeting of Stockholders
9. Secretary Shinseki Announces $215 Million in Projects for Rural Veterans
10. Perot Systems Announces Special Financing Options for Stimulus Plan Healthcare Technology Upgrades
11. Medstrat Announces Integration of Echoes With MacPractices EMR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... , ... February 19, 2017 , ... Braun Industries will ... Conference & Exposition, the event will take place February 23-25, 2017 at the Calvin ... be in Booth #909 with three new ambulances on display. , ...
(Date:2/19/2017)... ... 19, 2017 , ... "At your fingertips" electronic access to ... the Delaware Health Information Network (DHIN) have partnered to improve connectivity of this ... information exchange, DHIN stores and shares real-time health data for more than 2 ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March 1, 2017 — ... looking to reduce their regulatory burden? Pay dividends in enhanced and predictable ...
(Date:2/18/2017)... Lewisberry, PA (PRWEB) , ... February 17, 2017 , ... ... more about the Stannah Stairlift and other Butler products. Ken was impressed with ... team, and agreed to endorse the product on his show. This endorsement by ...
(Date:2/18/2017)... , ... February 17, 2017 , ... Park Cities Pet ... Behave” Show on the Pet Life Radio network. The episode, which was posted ... of topics including: what factors led to Park Cities Pet Sitter’s being awarded the ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , Feb. 17, 2017  Noble Capital Markets announced ... Pharma Inc. (Nasdaq: EPIX ). The report ... Kumar Raja , PhD. ESSA Pharmaceuticals is ... resistant prostate cancer (CRPC). Its lead compound EPI-506, is ... amino-terminal domain of the androgen receptor, thereby has potential ...
(Date:2/16/2017)... -- DaVita Inc. (NYSE: DVA ) today announced ... Net income attributable to DaVita Inc. for ... million, or $0.80 per share and $880 million, or $4.29 ... to DaVita Inc. for the quarter and year ended December ... million, or $0.98 per share, and $789 million, or $3.85 ...
(Date:2/16/2017)... -- Newly published research from the CVS Health (NYSE: ... private retailer can play in restricting access to tobacco ... in the American Journal of Public Health , ... all CVS Pharmacy stores reduced the number of cigarette ... impact on those who bought cigarettes exclusively at CVS ...
Breaking Medicine Technology: